IN8bio (NASDAQ:INAB) Price Target Cut to $12.50

IN8bio (NASDAQ:INABGet Free Report) had its price objective reduced by investment analysts at HC Wainwright from $14.00 to $12.50 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright also issued estimates for IN8bio’s Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.13) EPS and Q4 2025 earnings at ($0.14) EPS.

Separately, Laidlaw started coverage on IN8bio in a report on Monday, March 18th. They set a “buy” rating and a $7.50 price objective on the stock.

Get Our Latest Report on IN8bio

IN8bio Price Performance

Shares of INAB opened at $1.04 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.10 and a current ratio of 4.10. The firm has a market cap of $45.88 million, a PE ratio of -1.14 and a beta of 0.05. The firm’s 50 day moving average price is $1.11 and its 200 day moving average price is $1.16. IN8bio has a twelve month low of $0.65 and a twelve month high of $3.48.

IN8bio (NASDAQ:INABGet Free Report) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.05). As a group, research analysts expect that IN8bio will post -0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On IN8bio

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rock Creek Group LP grew its holdings in IN8bio by 98.3% in the 3rd quarter. Rock Creek Group LP now owns 151,314 shares of the company’s stock valued at $157,000 after buying an additional 75,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc increased its stake in IN8bio by 85.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 78,624 shares of the company’s stock valued at $109,000 after acquiring an additional 36,179 shares during the period. Finally, AIGH Capital Management LLC acquired a new position in IN8bio in the 4th quarter valued at approximately $5,216,000. 92.05% of the stock is owned by institutional investors and hedge funds.

About IN8bio

(Get Free Report)

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.

Recommended Stories

Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with's FREE daily email newsletter.